An evaluation method for nonlinear local disposition in rat liver and kidney. 2004

Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
Department of Biopharmaceutics and Drug Metabolism, School of Graduate Pharmaceutical Science, Kyoto University, Kyoto 606-8501, Japan.

A two-sampling sites method was developed to separately estimate the nonlinear local disposition in the liver and kidney by sampling blood simultaneously from the hepatic vein and an artery after intravenous administration. Using this method, it was attempted to predict the renal elimination from the systemic and hepatic elimination. Etoposide, a substrate of both P-glycoprotein and CYP3A, was used as a model drug. The blood samples from the hepatic vein and an artery were simultaneously taken from a rat after intravenous administration of etoposide at a dose of 20 or 80 mg/kg. At a dose of 20 mg/kg, the total clearance (CL), hepatic clearance (CLH), and renal clearance (CLR=CL-CLH), which were almost constant, were 2.82 +/- 0.24, 0.742 +/- 0.214, and 2.09 +/- 0.34 l/h/kg, respectively. At a dose of 80 mg/kg, CL and CLR considerably decreased with an increase in plasma concentration, whereas CLH slightly decreased. By means of the two-sampling sites method, we estimated the local drug disposition in the liver and kidney. The present local pharmacokinetic method would be applicable to assess the local disposition of other drugs that are mainly metabolized in these organs.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005263 Femoral Artery The main artery of the thigh, a continuation of the external iliac artery. Common Femoral Artery,Arteries, Common Femoral,Arteries, Femoral,Artery, Common Femoral,Artery, Femoral,Common Femoral Arteries,Femoral Arteries,Femoral Arteries, Common,Femoral Artery, Common
D006503 Hepatic Veins Veins which drain the liver. Hepatic Vein,Vein, Hepatic,Veins, Hepatic

Related Publications

Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
May 1999, Journal of pharmaceutical sciences,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
August 1996, The Journal of pharmacy and pharmacology,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
November 1978, Toxicology and applied pharmacology,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
September 1990, The Journal of pharmacy and pharmacology,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
February 1992, Journal of pharmaceutical sciences,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
March 1997, Drug metabolism and disposition: the biological fate of chemicals,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
October 1985, Biochemical pharmacology,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
September 1994, Biological & pharmaceutical bulletin,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
January 2000, Journal of pharmaceutical sciences,
Takako Kato, and Kiyoshi Yamaoka, and Yoshinobu Takakura
January 2000, Journal of pharmacological and toxicological methods,
Copied contents to your clipboard!